Mobilization of hematopoietic blood stem cells using the drug empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases

M. O. Bagova; Багова М. О.; Y. K. Mangasarova; Мангасарова Я. К.; A. U. Magomedova; Магомедова А. У.; O. V. Margolin; Марголин О. В.; E. S. Nesterova; Нестерова Е. С.; L. G. Gorenkova; Горенкова Л. Г.; R. R. Abdurashidova; Абдурашидова Р. Р.; Yu. A. Chabaeva; Чабаева Ю. А.; I. V. Galtseva; Гальцева И. В.; I. M. Nakastoev; Накастоев И. М.; V. S. Galuzyak; Галузяк В. С.; O. N. Bayteryakova; Байтерякова О. Н.; A. A. Shcherbakova; Щербакова А. А.; M. A. Telyashov; Теляшов М. А.; V. K. Spitsyn; Спицын В. К.; D. A. Sukhorukov; Сухоруков Д. А.; E. E. Zvonkov; Звонков Е. Е.

doi:10.18565/pharmateca.2023.11.44-50

Mobilization of hematopoietic blood stem cells using the drug empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases

Authors: Bagova M.O.¹, Mangasarova Y.K.¹, Magomedova A.U.¹, Margolin O.V.¹, Nesterova E.S.¹, Gorenkova L.G.¹, Abdurashidova R.R.¹, Chabaeva Y.A.¹, Galtseva I.V.¹, Nakastoev I.M.¹, Galuzyak V.S.¹, Bayteryakova O.N.¹, Shcherbakova A.A.¹, Telyashov M.A.¹, Spitsyn V.K.¹, Sukhorukov D.A.¹, Zvonkov E.E.¹
Affiliations:
1. National Medical Research Center for Hematology, Department of Chemotherapy for Lymphatic Tumors with a Unit of Bone Marrow and Hematopoietic Stem Cell Transplantation with Day Hospital
Issue: Vol 30, No 11 (2023)
Pages: 44-50
Section: Original articles
URL: https://journals.eco-vector.com/2073-4034/article/view/625809
DOI: https://doi.org/10.18565/pharmateca.2023.11.44-50
ID: 625809

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Objective. Evaluation of the effectiveness and safety of the empegfilgrastim (Extimia^®, BIOCAD) for various modes of mobilization of hematopoietic stem cells (HSCs) in patients with lymphoproliferative diseases (LPDs).

Methods. The study included 32 patients with LPDs who were treated at the National Medical Research Center for Hematology from October 2022 to April 2023. Mobilization of hematopoietic stem cells using empegfilgrastim at a dose of 7.5 mg in a “stable state of hematopoiesis” was carried out in 16 patients; and another 16 patients, drug was administered one day after polychemotherapy (PCT). A complete blood count and the blood CD34⁺ cell concentration at a “stable state of hematopoiesis” were estimated on the 4th and 5th days, and after the previous PCT – on the 8th and 9th days after the administration of empegfilgrastim. Leukapheresis was started if the CD34⁺ cell concentration exceeded 10 cells/μl, and the number of leukocytes in the blood was >5×10⁹/l. HSC mobilization was considered effective when the CD34⁺ cell count was ≥2 million × 10⁶/kg body weight. To analyze the obtained data, standard methods of descriptive statistics and frequency analysis were used.

Results. Mobilization of HSCs was effective in 20 (62.5%) of 32 patients. There were no statistically significant differences depending on the mode of HSC mobilization (P=0.76). Such factors as age, bone marrow damage, stage of the disease, presence of bulky disease, number of previous courses of chemotherapy, antitumor response status, radiation therapy, grade 3–4 anemia did not correlate with unsuccessful mobilization of HSCs. Mobilization of HSCs was more often effective in patients with Hodgkin lymphoma than in non-Hodgkin lymphomas: 55 and 25%, respectively (P=0.15).

Conclusion. The use of empegfilgrastim in a single fixed dose of 7.5 mg led to effective mobilization of HSCs in 62.5% of patients with LPDs.

Keywords

lymphoproliferative diseases, mobilization of hematopoietic stem cells, autologous transplantation, empegfilgrastim

Full Text

About the authors

M. O. Bagova

National Medical Research Center for Hematology, Department of Chemotherapy for Lymphatic Tumors with a Unit of Bone Marrow and Hematopoietic Stem Cell Transplantation with Day Hospital

Author for correspondence.
Email: mbagova89@mail.ru
ORCID iD: 0000-0002-8932-8197

Cand. Sci. (Med.)., Hematologist at the Department of Chemotherapy of Lymphatic Tumors with a Unit of Bone Marrow and Hematopoietic Stem Cell Transplantation with a Day Hospital

Russian Federation, Moscow

References

Моталкина М.С., Кулева С.А., Алексеев С.М. и др. Мобилизация гемопоэтических стволовых клеток: прошлое, настоящее и будущее, Педиатр. 2016;7(2). [Motalkina M.S., Kuleva S.A., Alekseev S.M. and others. Mobilization of hematopoietic stem cells: past, present and future, Pediatrician. 2016;7(2). (In Russ.)]. doi: 10.17816/PED7296-103.
Свирновский А.И. Резистентность опухолевых клеток к терапевтическим воздействиям как медико-биологическая проблема? Международные обзоры: клиническая практика и здоровье. 2014. С. 15–38. [Svirnovsky A.I. Resistance of tumor cells to therapeutic influences as a medical and biological problem? International reviews: clinical practice and health. 2014. P. 15–38. (In Russ.)].
Luo Ch., et al. Efcacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials. Stem. Cell Res Ther. 2022;13:123. doi: 10.1186/s13287-022-02802-6.
Passweg J.R., Baldomero H., Ciceri F., et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant. 2023;58:647–58. doi: 10.1038/s41409-023-01943-3.
Грицаев С.В., Кузяева А.А., Волошин С.В. и др. Заготовка трансплантата для аутологичной трансплантации гемопоэтических стволовых клеток онкогематологическим больным: частота и причины. Русский медицинский журнал. 2013;1:30–5. [Gritsaev S.V., Kuzyaeva A.A., Voloshin S.V. etc. Procurement of a graft for autologous transplantation of hematopoietic stem cells in hematological oncology patients: frequency and reasons. Russian medical journal. 2013;1:30–5. (In Russ.)].
To L.B., Levesque J.P., Herbert K.E. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118:4530–40.
Kim M.G., Han N., Lee E.K., Kim T. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant. 2015; 50:523–30.
Bruns I., Steidl U., Fischer J.C., et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematol. 2008;93:347–55.
Lapidot T., Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002;30(9):973–81.
Schmitt M., et al. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G‐CSF. Vox sanguinis. 2016;111(2):178–86.
Bakanay Ş.M., Demirer T. Novel agents and approaches for stem cell mobilization in normal donors and patients. Bone Marrow Transplant. 2012;47(9):1154–63.
Bruns .I, Steidl U., Kronenwett R., et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+progenitors in patients with mul- tiple myeloma. Transfusion. 2006;46:180–85.
Fruehauf S., Klaus J., Huesing J., et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant. 2007;39:743–50.
Herbert K.E., Gambell P., Link E.K., et al. Peg filgrastim compared with filgrastim for cy tokine-alone mobilization of autologous haema topoietic stem and progenitor cells. Bone Marrow Transplant. 2013;48:351–56.
Hosing C., Qazilbash M.H., Kebriaei P., et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol. 2006;133:533–37.
Isidori A., Tani M., Bonifazi F., et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematol. 2005;90:225–31.
Nosari A., Cairoli R., Ciapanna D., et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytincontaining regimens. Bone Marrow Transplant. 2006;38:413–16.
Willis F., Woll P., Theti D., et al. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. Bone Marrow Transplant. 2009;43:927–34.
Kuan J.-W., et al. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization. Transfus Apher Sci. 2015;53(2):196–204.
Russell N., et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy. Haematol. 2008;93(3):405–12. Doi.org/10.3324/haematol.11287.
Costa L.J., Kramer C., Hogan K.R. Pegfilgrastim versus filgrastim based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012;52(11):2375–81. 2995.2012.03579.x.
Flomenberg N., DiPersio J., Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol. 2005;114(4):198–205. doi: 10.1159/000088410.
Нестерова Е.С., Сайдуллаева А.Ф., Шерстнев Д.Г. и др. Эффективность и безопасность применения препарата эмпэгфилграстим (Экстимия®, БИОКАД) у пациентов с лимфопролиферативными заболеваниями, получающих цитотоксическую терапию: результаты второго промежуточного анализа многоцентрового ретроспективно-проспективного наблюдательного пострегистрационного исследования LEGERITY. Современная онкология. 2022;24(1):80–8. [Nesterova E.S., Saidullaeva A.F., Sherstnev D.G. et al. Efficacy and safety of the drug empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of the second interim analysis of the multicenter retrospective-prospective observational post-registration study LEGERITY. Modern oncology. 2022;24(1):80–8. (In Russ.)]. doi: 10.26442/18151434.2022.1.201493.
Wuchter P., Ran D., Bruckner T. Poor Mobilization of Hematopoietic Stem Cells Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation. Biol Blood Marrow Transplant. 2010;16:490–99. doi: 10.1016/j.bbmt.2009.11.01.
Cesana C., Carlo-Stella C., Regazzi E., et al. CD34+ cells mobilized by cyclophosphamide and granulocyte colony stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Bone Marrow Transplant. 1998;21:561–8.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Mobilization of hematopoietic blood stem cells using the drug empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases

Full Text

Abstract

Keywords

Full Text

About the authors

References

Supplementary files

This website uses cookies